Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers

BioDrugs - United Kingdom
doi 10.1007/s40259-015-0149-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Transitioning Between Biologics

SKIN The Journal of Cutaneous Medicine
2019English

Convergence and Divergence in the EU: Lessons From Italy

Intereconomics
ManagementFinanceBusinessEconomicsAccountingEconometrics
2019English

Analysing the Links Between National Capitals and Brussels in EU Foreign Policy

Western European Politics
International RelationsPolitical Science
2013English

FDA Biosimilar Action Plan: Could Improving Pharmacovigilance of Biologics Improve Patient and Physician Confidence in Biosimilars?

Expert Opinion on Drug Safety
MedicinePharmacology
2020English

Divergence-Based Classification in Learning Vector Quantization

Neurocomputing
Computer Science ApplicationsArtificial IntelligenceCognitive Neuroscience
2011English

Analysis of National Pharmacovigilance Data Associated With Statin Use in Korea

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2017English

Optically Active Centers in Eu Implanted, Eu in Situ Doped GaN, and Eu Doped GaN Quantum Dots

Journal of Applied Physics
AstronomyPhysics
2009English

National Translation of the Eu Landfill Directives

International Journal of Sustainable Development and Planning
DevelopmentManagementMonitoringRenewable EnergySustainabilityPlanningPolicyLawthe EnvironmentGeography
2006English

The Devil Is in the Data: Differences in Drug Persistence Between SNIIRAM, the French National Health Insurance Database, and Psoriasis Biologics Intervention Registers

British Journal of Dermatology
DermatologyMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy